Effect of EZH2 and BET bromodomain inhibition, alone and combined, on NUT carcinoma gene expression. Effect of EZH2 and BET bromodomain inhibition, alone and combined, on NUT carcinoma gene expression

To determine mechanisms of synergy between EZH2 and BRD4-NUT, we treated NUT carcinoma cell lines with EZH2 inhibitor, tazemetostat, and/or BET bromodomain inhibitors (ABBV075 pan-BET inhibitor or ABBV744 BD2-selective inhibitor). We then performed gene expression profiling analysis using data obtained from RNA-seq of 2 different NUT carcinoma cell lines at two time points, 6h and 96h. Overall design: Comparative gene expression profiling analysis of RNA-seq data for PER-403 and 10-15 NUT carcinoma cells treated with ABBV-744 or ABBV075 alone for 6h, tazemetostat alone for 96h, or tazemetostat combined with ABBV075 for 96h.